Compare VF Corp (VFC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VF Corp vs Viatris Inc — how do they compare? VF Corp trades at $12.94 (market cap $5.08B), while Viatris Inc trades at $16.45 (market cap $18.95B). The key difference: Viatris Inc is far larger — about 3.7× VF Corp's market cap, and Viatris Inc pays the higher dividend (2.91%). Which is the better fit depends on your goals.
| VFC | VTRS | |
|---|---|---|
Market Cap | $5.08B | $18.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $21.55 | $17.86 |
52-Week Low | $12.91 | $9.49 |
Enterprise Value | $9.36B | $31.07B |
Dividend Yield | 2.79% | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VFC trades at $13.20, down 1.86% on the day, with a bearish technical outlook despite attractive valuation metrics including a P/E of 19.13 and P/S of 0.55. Recent earnings showed mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The company faces challenges with Vans brand weakness offsetting strength in Outdoor brands, though management has raised fiscal 2027 sales guidance. Cash flow trends show improvement with 2026 projecting positive net cash flow of $32 million.
The investment case balances discounted valuation against execution risks. Analyst consensus leans neutral with a $17.38 price target representing 32% upside potential. Key risks include persistent Vans underperformance, consumer sentiment headwinds, and debt management challenges. The turnaround story depends on successful brand execution and margin improvement in the second half of 2026.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
